Please Wait.....
Report
Global Congenital Adrenal Hyperplasia Treatment Market Report and Forecast 2023-2031
Market Report I 2023-04-13 I 147 Pages I EMR Inc.
Global Congenital Adrenal Hyperplasia Treatment Market Report and Forecast 2023-2031
Global Congenital Adrenal Hyperplasia Treatment Market Outlook
The growth of the global congenital adrenal hyperplasia treatment market is being driven by the increasing prevalence of the condition worldwide and the growing investment in research and development activities. The global congenital adrenal hyperplasia is likely to grow at a rate of 7.75% during the forecast period of 2023-2031.
Congenital Adrenal Hyperplasia Treatment Market: Introduction
Global congenital adrenal hyperplasia treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments. Congenital adrenal hyperplasia is a group of genetic disorders that affect the adrenal glands, causing an insufficient production of essential hormones. Treatment options for congenital adrenal hyperplasia include medication, hormone replacement therapy, and surgery. The report covers the market for congenital adrenal hyperplasia treatment and provides a detailed analysis of the market size, growth, and trends.
The congenital adrenal hyperplasia treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as gene therapy, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.
Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of CONGENITAL ADRENAL HYPERPLASIA, potentially improving patient outcomes and reducing healthcare costs. As a result, the global CONGENITAL ADRENAL HYPERPLASIA treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.
Congenital Adrenal Hyperplasia Epidemiology
The global epidemiology of congenital adrenal hyperplasia varies based on factors such as ethnicity, geographic location, and the type of congenital adrenal hyperplasia. Improved awareness, new-born screening programs, and further epidemiological studies are crucial to better understand the distribution and determinants of congenital adrenal hyperplasia, which can aid in the development of more effective treatments and prevention strategies.
Congenital adrenal hyperplasia affects approximately 1 in 10,000 to 18,000 live births worldwide, with varying prevalence based on ethnicity and geographic region. The most common form of congenital adrenal hyperplasia is 21-hydroxylase deficiency, accounting for over 90% of cases. Early diagnosis and appropriate treatment are crucial in managing the condition and preventing complications.
Congenital Adrenal Hyperplasia Treatment Market Segmentations
The market can be categorised into diagnosis method, treatment method, therapeutic channel, and region.
Market Breakup by Diagnosis Method
- Prenatal Testing
? Amniocentesis
? Chorionic Villus Sampling
- Physical Exam
- Blood and Urine Tests
- Genetic Testing
Market Breakup by Treatment Method
- Medication
- Medications
- Physical Exams
- Reconstructive Surgery
Market Breakup by Therapeutic Channel
- Public
- Private
Market Breakup by Region
- North America
? United States of America
? Canada
- Europe
? United Kingdom
? Germany
? France
? Italy
? Others
- Asia Pacific
? China
? Japan
? India
? ASEAN
? Australia
? Others
- Latin America
? Brazil
? Argentina
? Mexico
? Others
- Middle East and Africa
? Saudi Arabia
? United Arab Emirates
? Nigeria
? South Africa
? Others
Congenital Adrenal Hyperplasia Treatment Market Scenario
The market is expected to grow at a significant rate during the forecast period of 2023-2031. The increasing prevalence of the disease, rising awareness, and growing investment in research and development activities are the key drivers of the market. North America dominates the market, followed by Europe and Asia Pacific. The leading players in the market are focusing on the development of new drugs and therapies and adopting various strategies to strengthen their position in the market.
North America dominates the congenital adrenal hyperplasia treatment market, followed by Europe and Asia Pacific. The high prevalence of congenital adrenal hyperplasia in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for congenital adrenal hyperplasia treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.
Key Players in the Global Congenital Adrenal Hyperplasia Treatment Market
The report gives an in-depth analysis of the key players involved in the congenital adrenal hyperplasia treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Neurocrine Bioscience
- Johnson and Johnson
- Sanofi
- Zydus Lifesciences Ltd.
- GSK plc
- BridgeBio, Inc.
- Millendo Therapeutics, Inc.
- Spruce Biosciences
- EffRx Pharmaceuticals
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Congenital Adrenal Hyperplasia Treatment Disease Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Model
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Congenital Adrenal Hyperplasia Treatment Market
6.1 Global Congenital Adrenal Hyperplasia Treatment Market Overview
6.2 Global Congenital Adrenal Hyperplasia Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Historical Congenital Adrenal Hyperplasia Treatment Market Volume (2016-2022)
6.2.1.2 Global Forecast Congenital Adrenal Hyperplasia Treatment Market Volume (2023-2031)
6.2.2 Global Congenital Adrenal Hyperplasia Treatment Market by Diagnosis Method
6.2.2.1 Market Overview
6.2.2.1.1 Prenatal Testing
6.2.2.1.1.1 Amniocentesis
6.2.2.1.1.2 Chorionic Villus Sampling
6.2.2.1.2 Physical Exam
6.2.2.1.3 Blood and Urine Tests
6.2.2.1.4 Genetic Testing
6.2.3 Global Congenital Adrenal Hyperplasia Treatment Market by Treatment Method
6.2.3.1 Market Overview
6.2.3.1.1 Medications
6.2.3.1.2 Physical Exams
6.2.3.1.3 Reconstructive Surgery
6.3 Global Congenital Adrenal Hyperplasia Treatment Market by Therapeutic Channel
6.3.1 Market Overview
6.3.1.1 Public
6.3.1.2 Private
6.4 Global Congenital Adrenal Hyperplasia Treatment Market by Region
6.4.1 Market Overview
6.4.1.1 North America
6.4.1.1.1 Historical Trend (2016-2022)
6.4.1.1.2 Forecast Trend (2023-2031)
6.4.1.2 Europe
6.4.1.2.1 Historical Trend (2016-2022)
6.4.1.2.2 Forecast Trend (2023-2031)
6.4.1.3 Asia Pacific
6.4.1.3.1 Historical Trend (2016-2022)
6.4.1.3.2 Forecast Trend (2023-2031)
6.4.1.4 Latin America
6.4.1.4.1 Historical Trend (2016-2022)
6.4.1.4.2 Forecast Trend (2023-2031)
6.4.1.5 Middle East and Africa
6.4.1.5.1 Historical Trend (2016-2022)
6.4.1.5.2 Forecast Trend (2023-2031)
7 North America Congenital Adrenal Hyperplasia Treatment Market
7.1 United States of America
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2 Canada
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
8. Europe Congenital Adrenal Hyperplasia Treatment Market
8.1 United Kingdom
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2 Germany
8.2.3 Historical Trend (2016-2022)
8.2.4 Forecast Trend (2023-2031)
8.3 France
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4 Italy
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
9 Asia Pacific Congenital Adrenal Hyperplasia Treatment Market
9.1 China
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2 Japan
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 India
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 ASEAN
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5 Australia
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
10 Latin America Congenital Adrenal Hyperplasia Treatment Market
10.1 Brazil
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2 Argentina
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Mexico
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
11 Middle East and Africa Congenital Adrenal Hyperplasia Treatment Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 United Arab Emirates
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Nigeria
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 South Africa
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
12 Current Scenario Evaluation
12.1 Emerging Therapies & Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
12.4.1.1 US FDA
12.4.1.2 EU EMA
12.4.1.3 INDIA CDSCO
12.4.1.4 JAPAN PMDA
12.4.1.5 Others
13 Challenges & Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop- out Analysis
13.3 Awareness and Prevention Gaps
14 Global Congenital Adrenal Hyperplasia Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter's Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Market Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Neurocrine Bioscience
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Johnson and Johnson
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Sanofi
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Zydus Lifesciences Ltd.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 GSK plc
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 BridgeBio, Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Millendo Therapeutics, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Spruce Biosciences
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 EffRx Pharmaceuticals
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
16 Recommendations and Discussion
17 Global Congenital Adrenal Hyperplasia Treatment Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security